SI2207770T1 - Drivati 1,2,3-triazola za uporabo kot zaviralci stearoil-coa-dezaturaze - Google Patents

Drivati 1,2,3-triazola za uporabo kot zaviralci stearoil-coa-dezaturaze

Info

Publication number
SI2207770T1
SI2207770T1 SI200830349T SI200830349T SI2207770T1 SI 2207770 T1 SI2207770 T1 SI 2207770T1 SI 200830349 T SI200830349 T SI 200830349T SI 200830349 T SI200830349 T SI 200830349T SI 2207770 T1 SI2207770 T1 SI 2207770T1
Authority
SI
Slovenia
Prior art keywords
stearoyl
triazole derivatives
coa desaturase
desaturase inhibitors
relates
Prior art date
Application number
SI200830349T
Other languages
English (en)
Inventor
Anne Marie Jeanne Bouillot
Alain Laroze
Lionel Trottet
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of SI2207770T1 publication Critical patent/SI2207770T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
SI200830349T 2007-11-09 2008-11-07 Drivati 1,2,3-triazola za uporabo kot zaviralci stearoil-coa-dezaturaze SI2207770T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0722077.5A GB0722077D0 (en) 2007-11-09 2007-11-09 Compounds
EP08846247A EP2207770B1 (en) 2007-11-09 2008-11-07 1, 2, 3-triazole derivatives for use as stearoyl-coa desaturase inhibitors
PCT/EP2008/065104 WO2009060053A1 (en) 2007-11-09 2008-11-07 1, 2, 3-triazole derivatives for use as stearoyl-coa desaturase inhibitors

Publications (1)

Publication Number Publication Date
SI2207770T1 true SI2207770T1 (sl) 2011-09-30

Family

ID=38858481

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200830349T SI2207770T1 (sl) 2007-11-09 2008-11-07 Drivati 1,2,3-triazola za uporabo kot zaviralci stearoil-coa-dezaturaze
SI200831183T SI2368887T1 (sl) 2007-11-09 2008-11-07 Derivati 1,2,3-triazola za uporabo kot zaviralci stearoil-coa-dezaturaze

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200831183T SI2368887T1 (sl) 2007-11-09 2008-11-07 Derivati 1,2,3-triazola za uporabo kot zaviralci stearoil-coa-dezaturaze

Country Status (32)

Country Link
US (2) US8486977B2 (sl)
EP (2) EP2207770B1 (sl)
JP (1) JP5491407B2 (sl)
KR (1) KR101577080B1 (sl)
CN (1) CN101918376B (sl)
AT (1) ATE512140T1 (sl)
AU (1) AU2008324172B2 (sl)
BR (1) BRPI0820471A2 (sl)
CA (1) CA2705113C (sl)
CO (1) CO6270331A2 (sl)
CR (1) CR11482A (sl)
CY (2) CY1112233T1 (sl)
DK (2) DK2207770T3 (sl)
DO (1) DOP2010000137A (sl)
EA (1) EA016621B1 (sl)
ES (2) ES2457521T3 (sl)
GB (1) GB0722077D0 (sl)
HK (2) HK1141528A1 (sl)
HR (2) HRP20110552T1 (sl)
IL (1) IL205152A (sl)
MA (1) MA31801B1 (sl)
ME (1) ME01962B (sl)
MX (1) MX2010005187A (sl)
MY (1) MY163126A (sl)
NZ (1) NZ584725A (sl)
PL (2) PL2207770T3 (sl)
PT (2) PT2207770E (sl)
RS (2) RS51918B (sl)
SI (2) SI2207770T1 (sl)
UA (1) UA107324C2 (sl)
WO (1) WO2009060053A1 (sl)
ZA (1) ZA201002596B (sl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0722077D0 (en) * 2007-11-09 2007-12-19 Smithkline Beecham Corp Compounds
GB0722075D0 (en) 2007-11-09 2007-12-19 Smithkline Beecham Corp Compounds
WO2010030046A1 (en) * 2008-09-15 2010-03-18 Daikin Industries, Ltd. Aqueous polymer dispersion composition and surface treatment agent
NZ592603A (en) * 2008-10-21 2013-02-22 Metabolex Inc Aryl gpr120 receptor agonists and uses thereof
FR2974089B1 (fr) * 2011-04-18 2014-04-25 Univ Nice Sophia Antipolis Derives de l'acadesine, produits et compositions les comprenant, leurs utilisations therapeutiques et leurs procedes de synthese.
US9233102B2 (en) 2012-03-07 2016-01-12 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
MX361761B (es) * 2012-09-17 2018-12-17 Hoffmann La Roche Derivados de triazol carboxamida.
IL227890A0 (en) * 2013-08-08 2014-01-30 Galderm Therapeutics Ltd Antiaging compounds containing bile acid and fatty acid conjugates
DK3250563T3 (da) 2015-01-30 2022-01-31 Neurocrine Biosciences Inc Substituerede triazoler og fremgangsmåder, der vedrører disse
KR20180036318A (ko) * 2016-09-30 2018-04-09 경북대학교 산학협력단 2-아미노-2-(1-도데실-1h-1,2,3-트리아졸-4-일)프로판-1,3-디올 유도체를 유효성분으로 포함하는 퇴행성 신경질환 및 우울증 예방 또는 치료용 약학적 조성물
CN110099898B (zh) 2016-10-24 2023-07-25 优曼尼蒂治疗公司 化合物及其用途
WO2018129403A1 (en) * 2017-01-06 2018-07-12 Yumanity Therapeutics Methods for the treatment of neurological disorders
KR102292989B1 (ko) 2017-03-29 2021-08-26 재단법인 아산사회복지재단 S1pr4를 타겟으로 하는 비알코올성 지방간염 예방 또는 치료용 조성물
EP3700934A4 (en) 2017-10-24 2021-10-27 Yumanity Therapeutics, Inc. COMPOUNDS AND USES OF THESE COMPOUNDS
JP2021522253A (ja) 2018-04-25 2021-08-30 ユマニティ セラピューティクス，インコーポレーテッド 化合物及びその使用
KR102017324B1 (ko) * 2018-04-30 2019-09-02 경북대학교 산학협력단 신규한 asm 활성 직접 억제 화합물 2-아미노-2-(1,2,3-트리아졸-4-일)프로판-1,3-디올 유도체 및 이의 용도
CN114656414B (zh) * 2022-05-24 2022-08-23 常熟华虞环境科技有限公司 三氮唑改性二氧化钛光催化剂及其制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722941A (en) 1978-06-07 1988-02-02 Kali-Chemie Pharma Gmbh Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
US4460372A (en) 1981-02-17 1984-07-17 Alza Corporation Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer
US4573996A (en) 1984-01-03 1986-03-04 Jonergin, Inc. Device for the administration of an active agent to the skin or mucosa
US4624665A (en) 1984-10-01 1986-11-25 Biotek, Inc. Method of transdermal drug delivery
US5223261A (en) 1988-02-26 1993-06-29 Riker Laboratories, Inc. Transdermal estradiol delivery system
US20070087363A1 (en) 1998-12-22 2007-04-19 Myriad Genetics, Incorporated Therapeutic methods, compounds and compositions
CA2398940C (en) 2000-02-24 2012-02-21 Xenon Genetics, Inc. Methods and compositions using stearoyl-coa desaturase to identify triglyceride reducing therapeutic agents
US7232662B2 (en) 2000-09-26 2007-06-19 Xenon Pharmaceuticals Inc. Methods and compositions employing a novel stearoyl-CoA desaturase-hSCD5
CN1312136C (zh) * 2002-04-26 2007-04-25 伊莱利利公司 用作速激肽受体拮抗剂的三唑衍生物
EP1638944A1 (en) * 2003-06-12 2006-03-29 Eli Lilly And Company Tachykinin receptor antagonists
AU2004261268B2 (en) * 2003-07-30 2009-03-12 Xenon Pharmaceuticals Inc. Piperazine derivatives and their use as therapeutic agents
CN101712653A (zh) 2003-07-30 2010-05-26 泽农医药公司 哒嗪衍生物和它们作为治疗剂的用途
WO2007046867A2 (en) 2005-05-19 2007-04-26 Xenon Pharmaceuticals Inc. Piperidine derivatives and their uses as therapeutic agents
WO2007046868A2 (en) 2005-05-19 2007-04-26 Xenon Pharmaceuticals Inc. Thiazolidine derivatives and their uses as therapeutic agents
WO2008073461A2 (en) * 2006-12-11 2008-06-19 Wyeth Ion channel modulators
GB0625605D0 (en) 2006-12-21 2007-01-31 Smithkline Beecham Corp Compounds
GB0625654D0 (en) 2006-12-21 2007-01-31 Smithkline Beecham Corp Compounds
GB0625604D0 (en) 2006-12-21 2007-01-31 Smithkline Beecham Corp Compounds
US20100120669A1 (en) 2007-02-28 2010-05-13 Anne Marie Jeanne Bouillot Thiadiazole derivatives, inhibitors of stearoyl-coa desaturase
EP2148868A1 (en) * 2007-05-15 2010-02-03 NeuroSearch A/S Novel aromatic heterocyclic carboxylic acid amide derivatives useful as potassium channel modulators
GB0714129D0 (en) 2007-07-19 2007-08-29 Smithkline Beecham Corp compounds
GB0715055D0 (en) 2007-08-02 2007-09-12 Smithkline Beecham Corp Compounds
GB0721419D0 (en) 2007-10-31 2007-12-12 Smithkline Beecham Corp Compounds
GB0722077D0 (en) * 2007-11-09 2007-12-19 Smithkline Beecham Corp Compounds
GB0722075D0 (en) 2007-11-09 2007-12-19 Smithkline Beecham Corp Compounds
GB0810913D0 (en) 2008-06-13 2008-07-23 Smithkline Beecham Corp Comppounds

Also Published As

Publication number Publication date
DK2207770T3 (da) 2011-09-12
EP2368887B8 (en) 2014-04-16
GB0722077D0 (en) 2007-12-19
ES2457521T3 (es) 2014-04-28
BRPI0820471A2 (pt) 2015-06-16
EP2368887A1 (en) 2011-09-28
CA2705113A1 (en) 2009-05-14
CN101918376A (zh) 2010-12-15
NZ584725A (en) 2012-05-25
MX2010005187A (es) 2010-05-27
RS51918B (en) 2012-02-29
US8486977B2 (en) 2013-07-16
AU2008324172B2 (en) 2012-03-15
JP2011503031A (ja) 2011-01-27
CN101918376B (zh) 2013-11-06
MA31801B1 (fr) 2010-10-01
WO2009060053A1 (en) 2009-05-14
US9051281B2 (en) 2015-06-09
ZA201002596B (en) 2010-12-29
ATE512140T1 (de) 2011-06-15
CY1112233T1 (el) 2015-12-09
DK2368887T3 (da) 2014-04-14
EP2207770A1 (en) 2010-07-21
EP2207770B1 (en) 2011-06-08
MY163126A (en) 2017-08-15
JP5491407B2 (ja) 2014-05-14
HK1160467A1 (en) 2012-08-17
PL2368887T3 (pl) 2014-07-31
HRP20140346T1 (hr) 2014-05-09
CY1115058T1 (el) 2016-12-14
UA107324C2 (uk) 2014-12-25
IL205152A0 (en) 2010-11-30
PT2207770E (pt) 2011-09-01
ES2366422T3 (es) 2011-10-20
EA016621B1 (ru) 2012-06-29
HK1141528A1 (en) 2010-11-12
ME01962B (en) 2012-02-29
EA201070588A1 (ru) 2010-10-29
RS53294B (en) 2014-08-29
PT2368887E (pt) 2014-05-15
CO6270331A2 (es) 2011-04-20
US20130281499A1 (en) 2013-10-24
SI2368887T1 (sl) 2014-05-30
CA2705113C (en) 2016-01-05
PL2207770T3 (pl) 2011-10-31
CR11482A (es) 2010-07-09
US20100297054A1 (en) 2010-11-25
HRP20110552T1 (hr) 2011-09-30
KR101577080B1 (ko) 2015-12-11
KR20100095574A (ko) 2010-08-31
EP2368887B1 (en) 2014-02-26
AU2008324172A1 (en) 2009-05-14
IL205152A (en) 2013-10-31
DOP2010000137A (es) 2010-08-15

Similar Documents

Publication Publication Date Title
HK1141528A1 (en) 1,2,3-triazole derivatives for use as stearoyl-coa desaturase inhibitors
WO2008074824A3 (en) Isoquinolinecarboxamides as inhibitors of stearoyl-coa desaturase (scd)
WO2008074834A3 (en) Isoquinolinecarboxamides as inhibitors of stearoyl-coa desaturase (scd)
DE602006021539D1 (en) Morpholine als 5ht2c-agonisten
MY143565A (en) Novel fluorocglycoside derivatives of pyrazoles: medicaments containing these compounds, and the use thereof
NZ592425A (en) Isoindoline compounds for use in the treatment of cancer
MY140638A (en) New heterocyclic compounds, which are active as inhibitors of beta-lactamases
MX2009005357A (es) Derivados de hidantoina usados como inhibidores de metaloproteinasas de matriz.
WO2008074832A3 (en) Isoquinolinecarboxamides as inhibitors of stearoyl-coa desaturase ( scd)
MX2009013501A (es) Compuestos piperidinicos y sus usos.
MX2010001020A (es) Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas.
MX2010013310A (es) Derivados de heterociclil urea para el tratamiento de infecciones bacterianas.
MX2010006108A (es) Inhibidores de estearoil-coa-desaturasa.
WO2008074833A3 (en) Compounds
MY148732A (en) Triazolium salts as par1 inhibitors, production thereof, and use as medicaments
TW200800993A (en) Organic compounds
MX2009005242A (es) Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo.
MX2012006287A (es) Activadores de azaindol glucocinasa.
UA87327C2 (ru) Производные бензимидазола, композиция, которая их содержит, их получение и применение
WO2010142956A3 (en) Aroylthiourea and arylthiocarbonylurea derivatives